As the annual U.S. Conference on HIV/AIDS (USCHA) kicks off in Washington, D.C., this week with a focus on aging with HIV, Gilead Sciences is rolling out a corresponding awareness campaign ...

Patients had better linkage to care for HIV and HIV was more frequently diagnosed when it was tested alongside other sexually transmitted infections (STIs), such as chlamydia and gonorrhea. The study ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

When President Donald Trump began his second term, the world was on the verge of a miracle: ending the global HIV pandemic by 2030. With the first strokes of his pen, Trump set to erase decades of ...

Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...

Botswana has been getting a lot of calls lately from across the African continent, prodding the nation — once “at risk of extinction” from HIV — to tell the world how they did the impossible: squash ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

For years, Philip Goulder has been obsessed with a particularly captivating idea: In the hunt for an HIV cure, could children hold the answers? Starting in the mid-2010s, the University of Oxford ...

For years, Philip Goulder has been obsessed with a particularly captivating idea: In the hunt for an HIV cure, could children hold the answers? Starting in the mid-2010s, the University of Oxford ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of the diverse variants of HIV. Neutralizing antibodies are proteins produced ...

Generating effective protection against HIV may require a complex vaccine consisting of a series of different viral proteins. Now, two trials of the potential components delivered via mRNA have ...